Evidence map›Paper›PMID 41898670›Full record

ReviewInternational journal of molecular sciences2026

B-Cell Depletion as Evidence for Shared Neuroimmune Pathways in Combined Central and Peripheral Demyelination: A Case Report and Literature Review.

Laura-Elena Cucu, Alina Săcărescu, Cristina Grosu, Victor Constantinescu, Laura Cristina Baciu, Gabriela-Smărăndița Asaftei-Titianu, Cristina Gațcan, Costin Chirica, Otilia Elena Frăsinariu, Emilian Bogdan Ignat

Abstract readCase ReportsReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laura-Elena CucuDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0000-1544-1325
Alina SăcărescuClinical Rehabilitation Hospital, 700661 Iasi, Romania.
Cristina GrosuClinical Rehabilitation Hospital, 700661 Iasi, Romania.
Victor ConstantinescuClinical Rehabilitation Hospital, 700661 Iasi, Romania.
Laura Cristina BaciuClinical Rehabilitation Hospital, 700661 Iasi, Romania.
Gabriela-Smărăndița Asaftei-TitianuDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Cristina GațcanDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Costin ChiricaDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0004-4813-8057
Otilia Elena FrăsinariuDepartment of Mother and Child Medicine-Pediatrics, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-5836-1517
Emilian Bogdan IgnatClinical Rehabilitation Hospital, 700661 Iasi, Romania.ORCID 0000-0002-6952-9741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combined central and peripheral demyelination (CCPD) is a rare neuroimmunological condition involving inflammatory demyelination of both the central nervous system (CNS) and peripheral nervous system (PNS). We report a chronic progressive CCPD case initially diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP) and treated with conventional CIDP-directed immunotherapies, with subsequent development of multiple sclerosis (MS)-like CNS demyelination. An extensive diagnostic evaluation excluded alternative infectious, metabolic, paraneoplastic, and antibody-mediated etiologies affecting either compartment. In the absence of a unifying pathogenic autoantibody, the combined clinical, radiological, cerebrospinal fluid, and electrophysiological findings support a shared immune-mediated process. Within this framework, B cells are implicated through antibody-independent mechanisms, including antigen presentation, pro-inflammatory cytokine production (e.g., IL-6), and amplification of Th1/Th17-driven inflammation. Interactions between B cells and the complement system via CR1 (CD35) and CR2 (CD21), together with dysfunction of the blood-brain barrier (BBB) and blood-nerve barrier (BNB), may facilitate parallel immune activation across both compartments. In this case, the observed radiological and electrophysiological stabilization under anti-CD20 therapy is consistent with a B-cell-driven pathogenic model in CCPD.

Indexed as

B-LymphocytesDemyelinating DiseasesLymphocyte DepletionNeuroimmunomodulationPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingHumansanti-CD20 therapyB cellschronic inflammatory demyelinating polyneuropathycombined central and peripheral demyelinationdemyelinationmultiple sclerosisneuroimmunology

Identifiers

PMID41898670
PMCPMC13027128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.